Data Sheet (Cat.No.T10200)

TargetMol

9-Hydroxyellipticine hydrochloride

Chemical Properties

CAS No. : 52238-35-4

Formula: C17H15ClN2O

Molecular Weight: 298.77

Storage: Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.



Biological Description

Description	9-Hydroxyellipticine hydrochloride is an inhibitor of Topo II and RyR, exhibiting antitumor, antioxidant, and catecholamine-releasing activities. It inhibits Hela S-3 and 293T cells with IC50s of 1.6 μM and 1.2 μM, respectively.
Targets(IC50)	Antioxidant,Topoisomerase
In vitro	9-Hydroxyellipticine hydrochloride exhibits concentration-dependent selective inhibition of p53 protein phosphorylation in Lewis lung carcinoma and SW480 (a human colon cancer cell line) within a range of 0.1 to 100 μM [4].
In vivo	9-Hydroxyellipticine (5 or 10 mg/kg, ip) induces chromosome clumping and sister chromatid exchange in murine bone marrow cells [1].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.3471 mL	16.7353 mL	33.4706 mL
5 mM	0.6694 mL	3.3471 mL	6.6941 mL
10 mM	0.3347 mL	1.6735 mL	3.3471 mL
50 mM	0.0669 mL	0.3347 mL	0.6694 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Renault G, et al. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells. Toxicol Appl Pharmacol. 1987 Jun 30;89(2):281-6.

Saeki K, et al. Cardioprotective effects of 9-hydroxyellipticine on ischemia and reperfusion in isolated rat heart. Jpn J Pharmacol. 2002 May;89(1):21-8.

Ohashi M, et al. Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: a possible anticancer mechanism. Jpn J Cancer Res. 1995 Sep;86(9):819-27.

Sugikawa E, Tsunoda S, Nakanishi N, Ohashi M. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein. Anticancer Res. 2001 Jul-Aug;21(4A):2671-5.